Diabetes Drug Mounjaro Found to Cut Heart Attack Risk by a Third for First Time A new study published in The BMJ has found that patients taking the diabetes medication Mounjaro (tirzepatide) are 33% less likely to suffer a heart attack compared to those on another type 2 diabetes medication.
This significant reduction in cardiovascular risk is being hailed as a major development in the treatment of cardiovascular disease.
The study involved nearly 53,000 people, making it one of the largest clinical trials ever conducted.